Core Viewpoint - Hunan Fangsheng Pharmaceutical Co., Ltd. announced a special cash dividend of 0.15 RMB per share for the fiscal year 2025, totaling approximately 65.86 million RMB, following the approval from the shareholders' meeting and the board of directors [1][3]. Dividend Distribution Plan - The special dividend is based on a total share capital of 439,081,360 shares, with a cash distribution of 0.15 RMB per share, amounting to a total cash dividend of 65,862,204 RMB [3]. - The dividend will be distributed to all shareholders registered with China Securities Depository and Clearing Corporation Limited, Shanghai Branch, as of the close of trading on the registration date [2]. Implementation Details - The cash dividends will be distributed through the clearing system of China Securities Depository and Clearing Corporation Limited, with shareholders who have completed designated transactions able to receive their dividends on the payment date [4]. - For shareholders who have not completed designated transactions, the dividends will be held by China Securities Depository and Clearing Corporation Limited until the transactions are completed [4]. Taxation Information - For individual shareholders holding unrestricted A-shares, the tax treatment varies based on the holding period: - Holding period within 1 month: 20% tax on dividends - Holding period between 1 month and 1 year: 10% effective tax rate - Holding period over 1 year: exempt from personal income tax [6][7]. - For qualified foreign institutional investors (QFII), a 10% corporate income tax will be withheld, resulting in a net dividend of 0.135 RMB per share [8]. Compliance and Inspection - The company received a non-compliance notice from the Hunan Provincial Drug Administration regarding the production of the raw material indobufen, due to outdated standards during the production process [10]. - The company is currently in the preparation stage for the market launch of indobufen and has initiated corrective actions to address the issues identified during the inspection [11].

Core Viewpoint - Fangsheng Pharmaceutical (603998) announced that its new production line for the active pharmaceutical ingredient (API) Indobufen does not meet regulatory requirements following an inspection by the Hunan Provincial Drug Administration [1] Group 1: Inspection Results - The inspection conducted on November 2025 revealed that the production line for Indobufen at the new facility in Hunan Wancheng Economic Development Zone was found non-compliant due to outdated standards used in the production of intermediate 1 [1] - The company received a GMP compliance inspection notice, indicating that the production address is being changed from 789 Lushong Road, Changsha, Hunan, to 368 Huanglong Road, Wancheng Economic Development Zone [1] Group 2: Current Status and Future Plans - Indobufen API was approved for market launch in June 2024, and the company is currently in the pre-market preparation stage, with no sales yet [1] - The company has addressed the issues identified during the inspection and plans to reapply for inspection promptly [1] Group 3: Market and Regulatory Environment - The pharmaceutical products are characterized by high technology, high risk, and high added value, making future sales subject to market changes and regulatory factors, which introduces uncertainty [1] - On January 9, it was noted that the Hunan Securities Regulatory Bureau issued a warning letter to the accounting firm involved in the audit of Fangsheng Pharmaceutical's 2024 annual report due to multiple violations [2]

Group 1: Stock Trading and Corporate Actions - Jia Mei Packaging's stock will resume trading on January 12, 2026, after a price increase of 230.48% from December 17, 2025, to January 6, 2026, which led to a temporary suspension for investigation [1] - Yanjiang Co. continues to suspend its stock trading due to uncertainties related to a potential major asset restructuring, with a trading plan expected to be disclosed by January 19, 2026 [1] - Shangluo Electronics' application for issuing convertible bonds has been accepted by the Shenzhen Stock Exchange [4] - Xianle Health plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global strategy and capital strength [4] - Hangyu Technology plans to sell up to 752,800 repurchased shares to supplement working capital [4] Group 2: Mergers and Acquisitions - Defu Technology has terminated its acquisition of 100% of Luxembourg Copper Foil due to additional restrictions imposed by the Luxembourg Ministry of Economy [2] - Defu Technology intends to acquire at least 51% of Huiru Technology through cash purchase and capital increase, with Huiru becoming a subsidiary post-transaction [3] Group 3: Financial Performance and Forecasts - Dechang Co. expects a net profit decrease of 51% to 61% for 2025, with automotive parts business growth offset by challenges in the home appliance sector [7] - Hebang Bio anticipates a net loss for 2025 due to asset impairment provisions [8] - Qu Mei Home expects negative profit figures for 2025, with a reported loss of approximately 66.93 million yuan for the first nine months of 2025 [9] - Jinzhongzi Liquor forecasts a net loss for 2025, although the loss is expected to narrow compared to the previous year [10] - Sichuang Electronics predicts a net loss of 265 million to 340 million yuan for 2025, attributed to competitive pressures and delayed customer orders [11] - Wansheng Co. anticipates a net loss for 2025 [12] - Weiyuan Co. expects a net loss for 2025 [13] - Kosen Technology forecasts a net loss for 2025 due to market demand fluctuations and strategic adjustments [13] - Zhongheng Group predicts a net loss for 2025 [13] - Xiantan Co. reported a chicken product sales revenue of 530 million yuan in December 2025, a year-on-year increase of 9.41% [13] Group 4: Shareholder Actions - Huate Gas shareholders plan to reduce their holdings by up to 2% through block trades between February 4 and April 30, 2026 [14] - Meidike's shareholder intends to reduce holdings by up to 1% through centralized bidding [14]

公司吲哚布芬原料药于 2024 年6 月获批上市，本次符合性检查为申请将生产地址由湖南省长沙市麓松 路789 号变更至湖南望城经济开发区铜官镇循环经济工业基地内黄龙路368号。公司吲哚布芬原料药及 制剂当前处于上市前准备阶段，尚未正式投放市场销售，本次检查不会对公司的生产经营产生实质性影 响。公司已针对检查中发现的问题进行了整改和完善，并将尽快重新申请检查。 格隆汇1月11日丨方盛制药(603998.SH)公布，近日，公司收到湖南省药品监督管理局(以下简称"药监 局")签发的《药品GMP 符合性检查告知书》。2025 年11 月，药监局对公司位于湖南望城经济开发区铜 官镇循环经济工业基地内的生产地址进行了检查，检查范围为原料药(吲哚布芬)；原料药车间(101车 间)D 区、F 区与 E 区吲哚布芬生产线。经检查，结论为不符合要求(主要系因在中间体 1 的生产中依据 的标准未更新到最新版本导致)。 ...

方盛制药（603998）(603998.SH)发布公告，近日，公司收到湖南省药品监督管理局签发的《药品GMP 符合性检查告知书》，2025年11月，药监局对公司位于湖南望城经济开发区铜官镇循环经济工业基地内 的生产地址进行了检查，检查范围为原料药(吲哚布芬);原料药车间(101车间)D区、F区与E区吲哚布芬生 产线。经检查，结论为不符合要求(主要系因在中间体1的生产中依据的标准未更新到最新版本导致)。 公司吲哚布芬原料药及制剂当前处于上市前准备阶段，尚未正式投放市场销售，本次检查不会对公司的 生产经营产生实质性影响。公司已针对检查中发现的问题进行了整改和完善，并将尽快重新申请检查。 医药产品因高科技、高风险、高附加值特点，其未来销售受市场变化、政策等诸多因素影响，存在不确 定性。请广大投资者谨慎决策，注意防范投资风险。 ...

公司吲哚布芬原料药及制剂当前处于上市前准备阶段，尚未正式投放市场销售，本次检查不会对公司的 生产经营产生实质性影响。公司已针对检查中发现的问题进行了整改和完善，并将尽快重新申请检查。 医药产品因高科技、高风险、高附加值特点，其未来销售受市场变化、政策等诸多因素影响，存在不确 定性。请广大投资者谨慎决策，注意防范投资风险。 智通财经APP讯，方盛制药(603998.SH)发布公告，近日，公司收到湖南省药品监督管理局签发的《药 品GMP符合性检查告知书》，2025年11月，药监局对公司位于湖南望城经济开发区铜官镇循环经济工 业基地内的生产地址进行了检查，检查范围为原料药(吲哚布芬);原料药车间(101车间)D区、F区与E区吲 哚布芬生产线。经检查，结论为不符合要求(主要系因在中间体1的生产中依据的标准未更新到最新版本 导致)。 ...